SPEECH AND LANGUAGE DISORDERS IN PATIENTS WITH HIGH-GRADE GLIOMA AND ITS INFLUENCE ON PROGNOSIS

被引:12
作者
THOMAS, R [1 ]
OCONNOR, AM [1 ]
ASHLEY, S [1 ]
机构
[1] INST CANC RES, SUTTON SM2 5PT, SURREY, ENGLAND
关键词
GLIOMA; PROGNOSIS; SPEECH DEFICIT;
D O I
10.1007/BF01059960
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One hundred and sixteen patients wiht high grade glioma were entered into a prospective phase two study and treated with accelerated radiotherapy from 1988 to 1993. In this cohort of patients we analysed speech deficit as a subdivision of global functional status in terms of incidence, category and prognosis for survival. Forty three patients (37%) had a speech deficit at presentation. Eighty percent of these had a component of expressive dysphasia, associated with considerable degree of awareness and distress. The overall median survival was 9.5 months. On univariate analysis, median survival in patients with speech difficulties (6 months) was worse than patients with normal speech (10.5 months) (log rang p = 0.005). Multivariate analysis established independent significance from age, Karnofsky Performance Status (KPS), gender, histological grade, extent of surgery and seizures. This paper highlights the importance of assessing individual categories of functional disability which in patients with high grade glioma include mobility, cognitive function and communication. Each of these factors may seriously affect an individual's activities of daily living, hence quality of life and separate analysis has a number of clinical implications. Firstly, with over a third of patients suffering speech difficulties, adequate speech therapy facilities should be freely available to score the degree of deficit, devise coping strategies and institute communication therapy. Secondly, an understanding of prognostic factors aids the critical analysis of phase two studies and the design and stratification of future prospective trials which should include an analysis of speech deficit. Thirdly, separating individual patients into good and bad prognostic groups can assist strategic management decisions.
引用
收藏
页码:265 / 270
页数:6
相关论文
共 25 条
[1]  
[Anonymous], 1990, J Neurooncol, V9, P47
[2]   A MEDICAL-RESEARCH-COUNCIL TRIAL OF 2 RADIOTHERAPY DOSES IN THE TREATMENT OF GRADE-3 AND GRADE-4 ASTROCYTOMA [J].
BLEEHEN, NM ;
STENNING, SP .
BRITISH JOURNAL OF CANCER, 1991, 64 (04) :769-774
[3]  
BRADA M, 1994, J NEUROONCOLOGY, V21, P20
[4]  
CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO
[5]  
2-2
[6]   QUALITY-OF-LIFE MEASUREMENTS IN PATIENTS WITH MALIGNANT DISEASE - A REVIEW [J].
CLARK, A ;
FALLOWFIELD, LJ .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1986, 79 (03) :165-169
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
CURRAN WJ, 1993, J CANCER I, V85, P769
[9]   RESULTS OF A RANDOMIZED TRIAL COMPARING BCNU PLUS RADIOTHERAPY, STREPTOZOTOCIN PLUS RADIOTHERAPY, BCNU PLUS HYPERFRACTIONATED RADIOTHERAPY, AND BCNU FOLLOWING MISONIDAZOLE PLUS RADIOTHERAPY IN THE POSTOPERATIVE TREATMENT OF MALIGNANT GLIOMA [J].
DEUTSCH, M ;
GREEN, SB ;
STRIKE, TA ;
BURGER, PC ;
ROBERTSON, JT ;
SELKER, RG ;
SHAPIRO, WR ;
MEALEY, J ;
RANSOHOFF, J ;
PAOLETTI, P ;
SMITH, KR ;
ODOM, GL ;
HUNT, WE ;
YOUNG, B ;
ALEXANDER, E ;
WALKER, MD ;
PISTENMAA, DA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (06) :1389-1396
[10]  
Goodglass H., 2000, BOSTON DIAGNOSTIC AP